Skip to contentpdufa.bio

ordastobart (INBRX-106)

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

ordastobart (INBRX-106) is an Inhibrx Biosciences, Inc. program in 1L PD-L1-high R/M HNSCC (HPV+ expansion). Its next catalyst is a Readout in Q4 2027.

INBX catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indications under review: 1L PD-L1-high R/M HNSCC (HPV+ expansion); Perioperative NSCLC. Sponsor: Inhibrx Biosciences, Inc. (INBX). We track 2 catalyst events for this program: 2 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Q4 2027INBXReadout · Q4 2027INBX

Specialist biotech funds holding INBX, 13F for the quarter ended September 30, 2026

FundSharesValue at quarter endFiling
Perceptive Advisors1,292,463$129.3 millionfiled November 16, 2026
Cormorant Asset Management50,000$5.0 millionfiled November 16, 2026

13F reports list long positions in common stock at quarter end, are due 45 days later, and show no short positions or later trades. Notes, warrants and other instruments are not counted as shares.

Questions

When is ordastobart (INBRX-106)'s next FDA decision or readout?

The next tracked catalyst for ordastobart (INBRX-106) is a Readout in Q4 2027.

What happened at ordastobart (INBRX-106)'s most recent FDA decision?

No FDA decision for ordastobart (INBRX-106) is in our archive yet.

What is ordastobart (INBRX-106) used for?

In our records ordastobart (INBRX-106) is under review or in development for 1L PD-L1-high R/M HNSCC (HPV+ expansion); Perioperative NSCLC.

Who makes ordastobart (INBRX-106)?

Inhibrx Biosciences, Inc. (INBX).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.